ProCE Banner Activity

Phase III HOVON97: Azacitidine Maintenance in Older Patients With AML and Refractory Anemia

Slideset Download
Conference Coverage
Azacitidine was well tolerated and significantly improved disease-free survival in older patients with anemia-refractory AML.

Released: December 18, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology